 Cannabinoids
"Cannabinoids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL.
| Descriptor ID |
D002186
|
| MeSH Number(s) |
D02.455.849.090
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cannabinoids".
Below are MeSH descriptors whose meaning is more specific than "Cannabinoids".
This graph shows the total number of publications written about "Cannabinoids" by people in UAMS Profiles by year, and whether "Cannabinoids" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 2 | 0 | 2 | | 2022 | 7 | 0 | 7 | | 2021 | 3 | 0 | 3 | | 2020 | 3 | 0 | 3 | | 2019 | 2 | 1 | 3 | | 2018 | 2 | 1 | 3 | | 2017 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2014 | 1 | 1 | 2 | | 2013 | 3 | 1 | 4 | | 2012 | 5 | 0 | 5 | | 2011 | 3 | 1 | 4 | | 2009 | 2 | 0 | 2 | | 2007 | 1 | 1 | 2 | | 1991 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cannabinoids" by people in Profiles over the past ten years.
-
Murray CH, Gannon BM, Winsauer PJ, Cooper ZD, Delatte MS. The Development of Cannabinoids as Therapeutic Agents in the United States. Pharmacol Rev. 2024 Aug 15; 76(5):915-955.
-
Humayun M, Suarez JI, Shah VA. Neurological Complications of Cannabinoids. Semin Neurol. 2024 Aug; 44(4):430-440.
-
Fujiwara R, Journey M, Al-Doori F, Bell P, Judge B, Miracle K, Ito K, Jones S. Potential neonatal toxicity of new psychoactive substances. Pharmacol Ther. 2023 08; 248:108468.
-
Joshi M, Joshi A, Bartter T. Marijuana and the Lung: Evolving Understandings. Med Clin North Am. 2022 Nov; 106(6):1093-1107.
-
Wilson CD, Zheng F, Fantegrossi WE. Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice. Psychopharmacology (Berl). 2022 Oct; 239(10):3237-3248.
-
Kearney-Ramos T, Herrmann ES, Belluomo I, Matias I, Vall?e M, Monlezun S, Piazza PV, Haney M. The Relationship Between Circulating Endogenous Cannabinoids and the Effects of Smoked Cannabis. Cannabis Cannabinoid Res. 2023 12; 8(6):1069-1078.
-
Cabanlong CV, Russell LN, Fantegrossi WE, Prather PL. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. Toxicol Sci. 2022 04 26; 187(1):175-185.
-
Wilson CD, Hiranita T, Fantegrossi WE. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal. Drug Alcohol Depend. 2022 07 01; 236:109468.
-
Forsyth AD, Kulik MC, Richmond McKnight T, Perkins AD, Balla A. University of California Cannabis Research Workshop, May 2021: Meeting Summary. Cannabis Cannabinoid Res. 2022 04; 7(2):152-155.
-
Shoeib AM, Benson LN, Mu S, MacMillan-Crow LA, Prather PL. Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death. Int J Mol Sci. 2022 Mar 11; 23(6).
-
Borodovsky JT, Sofis MJ, Sherman BJ, Gray KM, Budney AJ. Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints. Psychol Addict Behav. 2022 Aug; 36(5):515-525.
-
Shoeib AM, Yarbrough AL, Ford BM, Franks LN, Urbaniak A, Hensley LL, Benson LN, Mu S, Radominska-Pandya A, Prather PL. Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. Life Sci. 2021 Nov 15; 285:119993.
-
Leal EC, Moura LIF, Pirzgalska RM, Marques-da-Silva D, Ledent C, K?falvi A, Carvalho E. Diabetes and Cannabinoid CB1 receptor deficiency promote similar early onset aging-like changes in the skin. Exp Gerontol. 2021 10 15; 154:111528.
-
Stanciu CN, Brunette MF, Teja N, Budney AJ. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Psychiatr Serv. 2021 04 01; 72(4):429-436.
-
Pinson AO, Pouncey DL, Schleiff MA, Fantegrossi WE, Prather PL, Radominska-Pandya A, Boysen G, Miller GP. Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. Molecules. 2020 Oct 20; 25(20).
-
Yang JF, Williams AH, Penthala NR, Prather PL, Crooks PA, Zhan CG. Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands. ACS Chem Neurosci. 2020 10 21; 11(20):3455-3463.
-
Koturbash I, MacKay D. Cannabidiol and Other Cannabinoids: From Toxicology and Pharmacology to the Development of a Regulatory Pathway. J Diet Suppl. 2020; 17(5):487-492.
-
Patel RS, Kamil SH, Bachu R, Adikey A, Ravat V, Kaur M, Tankersley WE, Goyal H. Marijuana use and acute myocardial infarction: A systematic review of published cases in the literature. Trends Cardiovasc Med. 2020 07; 30(5):298-307.
-
Acheson A, Fantegrossi WE. Introduction to special issue: Therapeutic and abuse-related effects of cannabis and cannabinoids. Exp Clin Psychopharmacol. 2019 Aug; 27(4):299-300.
-
Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica. 2019 Dec; 49(12):1388-1395.
-
Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with ?9-Tetrahydrocannabinol and JWH-018. J Pharmacol Exp Ther. 2019 05; 369(2):259-269.
-
Tai S, Vasiljevik T, Sherwood AM, Eddington S, Wilson CD, Prisinzano TE, Fantegrossi WE. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Drug Alcohol Depend. 2018 11 01; 192:285-293.
-
Fantegrossi WE, Wilson CD, Berquist MD. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev. 2018 Feb; 50(1):65-73.
-
Prather PL. Preface to DMR special edition 'Cannabinoid receptors and ligands: therapeutic drug development and abuse potential'. Drug Metab Rev. 2018 02; 50(1):1-2.
-
Mount PF, Juncos LA. Obesity-Related CKD: When Kidneys Get the Munchies. J Am Soc Nephrol. 2017 12; 28(12):3429-3432.
-
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic Pot: Not Your Grandfather's Marijuana. Trends Pharmacol Sci. 2017 03; 38(3):257-276.
-
Tai S, Fantegrossi WE. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Curr Top Behav Neurosci. 2017; 32:249-262.
-
Budney AJ, Sargent JD, Lee DC. Confirmation of the trials and tribulations of vaping. Addiction. 2015 Nov; 110(11):1710-1.
-
Tai S, Nikas SP, Shukla VG, Vemuri K, Makriyannis A, J?rbe TU. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist. Psychopharmacology (Berl). 2015 Aug; 232(15):2751-61.
-
Dudok B, Barna L, Ledri M, Szab? SI, Szabadits E, Pint?r B, Woodhams SG, Henstridge CM, Balla GY, Nyilas R, Varga C, Lee SH, Matolcsi M, Cervenak J, Kacskovics I, Watanabe M, Sagheddu C, Melis M, Pistis M, Soltesz I, Katona I. Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling. Nat Neurosci. 2015 Jan; 18(1):75-86.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|